A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

• Status: Recruiting
• Trial end date: 2023-03-22
• Target enrollment: 0
• Participant gender: All

Summary

Study of safety and efficacy of UNR844 in subjects with presbyopia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals

Criteria

Inclusion Criteria:

• Written informed consent must be obtained before any assessment is performed

• Impaired near vision in each eye and when using both eyes, without any near correction

• Need a certain level of near correction

Exclusion Criteria:

• Impaired distance vision in either eye, with distance correction (if any)

• Severe short- or long-sightedness

• Any significant medical or clinical conditions affecting vision, the eyes or general health